Leerink Partners Downgrades Compass Therapeutics (NASDAQ:CMPX) to Market Perform

Leerink Partners cut shares of Compass Therapeutics (NASDAQ:CMPX) from an outperform rating to a market perform rating in a research report sent to investors on Friday, MarketBeat reports. The brokerage currently has $4.00 price target on the stock, down from their prior price target of $5.00.

A number of other research firms have also recently weighed in on CMPX. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a research note on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research note on Monday, November 11th. Finally, Wedbush reissued an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $6.75.

Compass Therapeutics Trading Down 13.2 %

Shares of Compass Therapeutics stock opened at $1.38 on Friday. The business’s fifty day simple moving average is $1.75 and its 200 day simple moving average is $1.42. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.34. The firm has a market capitalization of $189.87 million, a P/E ratio of -3.73 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Analysts predict that Compass Therapeutics will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CMPX. Rovin Capital UT ADV purchased a new stake in shares of Compass Therapeutics during the third quarter worth $25,000. Intech Investment Management LLC purchased a new position in shares of Compass Therapeutics in the third quarter valued at $30,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics during the 3rd quarter valued at $37,000. Cubist Systematic Strategies LLC purchased a new stake in Compass Therapeutics during the 2nd quarter worth about $41,000. Finally, Panagora Asset Management Inc. bought a new position in Compass Therapeutics in the 2nd quarter worth about $68,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.